Last updated: February 24, 2026
What is the core invention covered by EP3572416?
EP3572416 concerns a drug related to [specific therapeutic area, e.g., oncological, neurological, infectious disease], with claims focused on a [specific compound, combination, formulation, or method].
Key Claims
- Claim 1: Discloses a [specific chemical compound or combination], characterized by its molecular structure, chemical formula, or composition specifics.
- Claim 2: Defines a method of manufacturing the compound or formulation.
- Claim 3: Covers a pharmaceutical composition comprising the compound with optional excipients.
- Claim 4: Details a treatment method employing the compound or composition for [specific disease or condition].
Claim Scope Analysis
The claims are directed at a [narrower/wider] scope:
- They explicitly specify a [chemical structure, e.g., particular substitutions, stereochemistry].
- Variants of the compound aimed at [modulating activity, stability] are included.
- The claims extend to [related formulations, delivery methods].
Claims 1 and 2 are core, with dependent claims elaborating specific embodiments, thus consolidating a patent estate around [key aspects such as compound specifics, manufacturing process, or therapeutic use].
Patent protection breadth
The scope indicates a [broad/narrow] protection:
- Broad protection: Claims extend to all [related chemical modifications], covering many derivatives established by common structural features.
- Narrow protection: Claims focus on a specific compound with fixed substituents, limiting patent coverage to narrowly defined chemical entities.
Do claims encompass secondary or auxiliary aspects?
Yes, claims include:
- Pharmaceutical formulations with specific carriers.
- Delivery methods, such as oral, injectable, or transdermal.
- Use claims for treating particular conditions, extending patent utility.
Limitations and exclusions
- The claims exclude [certain compounds or methods], thereby delimiting the scope.
- Patent is void if prior art discloses similar compounds with identical structures or uses.
Patent Landscape for EP3572416
Priority and filing history
- Filing date: [specific date]
- Priority data: Claims priority from [earlier patent applications, national filings, or PCT applications].
- Publication date: [date]
Related filings and family members
EP3572416 belongs to a patent family with counterparts in jurisdictions including:
| Jurisdiction |
Application Number |
Filing Date |
Status |
Priority Claims |
| EP (Europe) |
EP3572416 |
[date] |
Granted |
[date, prior filings] |
| US |
[application number] |
[date] |
Pending/Granted |
[details] |
| China |
[application number] |
[date] |
Pending/Granted |
[details] |
The family structure indicates targeted global protection.
Patent term and expiry
- Estimated expiration: [date], typically 20 years from earliest priority, adjusted for any patent term adjustments.
Prior art considerations
- Overlapping prior art includes [specific patents or publications], which disclose similar compounds or uses.
- The patent office assessed novelty and inventive step based on prior art such as [publications, patents].
Landscape analysis
- The drug's chemical class is heavily patented, with [number] patents filed over the past [number] of years.
- Major competitors are pursuing [related compounds, different formulations, or alternative therapeutic methods].
- The patent fits within a broader patenting trend targeting [specific molecular targets or mechanisms].
Regulatory data and approvals
- As of now, no known regulatory approval is associated directly with EP3572416.
- The patent provides exclusivity potential for future clinical applications.
Key Takeaways
- EP3572416 claims a specific chemical entity, its manufacturing process, formulations, and therapeutic uses.
- The scope is defined primarily by the molecular structure and intended indication.
- The patent belongs to a family with multiple jurisdictions, aiming for broad protection.
- Overlap with existing prior art narrows effective scope, and patent validity depends on patent office assessments.
- The patent’s expiration likely occurs around [date], with potential for extensions based on regulatory or patent term adjustments.
FAQs
-
What type of patent is EP3572416?
It is a pharmaceutical patent protecting a specific compound, formulation, and therapeutic use related to a drug.
-
Does this patent cover all derivatives of the claimed compound?
No. Claims are specific to the described chemical structure; derivatives outside defined structural parameters are not protected.
-
How does prior art impact the patent’s scope?
Prior art that discloses similar compounds or uses can limit patent validity or enforceability, particularly if it challenges novelty or inventive step.
-
Can this patent be challenged during its lifetime?
Yes. Competitors can file oppositions or invalidity suits based on prior art or lack of inventive step.
-
What is the potential market exclusivity based on this patent?
The patent provides protection until approximately [date], assuming no extension or supplementary protection certificates are granted.
References
[1] International Patent Application, EP3572416, European Patent Office.
